Get started

Biotech

GOSS Penny Biotechology SHORTGOSS is a biotechnology penny stock without earnings valued based on future earnings potential based on a "pipeline" which is subject to a long timeline of FDA regulation. On the 30 minute chart. price is shown as being in the overvalued area in the upper VWAP band and well above the POC line of the long-range volume profile. The RSI indicator is now showing a bearish divergence as the relative strength is weakening. Price has bounced down from the resistance of the line representing two standard deviations above VWAP. The supply / demand zones are indicated by the Indicator applied which is authored by Luxalgo. Price has hit the supply zone lower border and is now in an early reversal. I see this as a swing short trade also played with taking put options. Stop loss is in the upper area of the red supply zone. Targets include first the POC line of the volume profile and then a final target at one STD below VWAP also being just above the demand zone. Alternatively put options at the strike of $ 1.50 for the May monthly expiration of 5/18 This trade will benefit from any expected pullback in the general markets.
NASDAQ:GOSSShort
by AwesomeAvani
LABD 3X BEAR BIOTECH LONG DAYTRADEAs shown on the 15-minute chart, LABD is bouncing between stardard deviations of the VWAP in a 6% price range fluctuation day to day. At the upper end it is reversing at the POC of the volume profile confluent with one standard deviation above VWAP while at the bottom it is bouncing from the bottom of the lower high volume area of the profile and two standard deviations below VWAP. I see this as an opportunity for a 6% upside long day trade especially if the general market is uptrending after the weekend. Alternatively, a 5 DTE call option with a strike of $ 15.50 or $16.00 looking for a 30-40% return on the premium over the upcoming week. ( The zero lag MACD confirms the buy signal.)
AMEX:LABDLong
by AwesomeAvani
ACHV a Biotech company after earningsACHV on the 4H seems to be demonstrating a "High Bull Flag Pattern" after a big uptrend to start the year. Earnings on Thursday 3/16 were quite favorable.On the relative volume indicator Friday, May 17th showed a paradoxical huge selling volume spike to finish out this week. ( I mislabelled this as upcoming on the chart) Paradoxically, the last earnings report in November was poor but resulted in strong upward price action. The MACD histogram is at the zero line. Will ACHV resume the uptrend after earnings? Was the selling volume an institutional trader fake out to set up a lower price to buy call options? According to Tip Ranks, the analysts give ACHV a high rating with significant upside. See the link below Who knows but this may be worth watching for signs of buying volume and accumulation to fuel bullish momentum.
NASDAQ:ACHV
by AwesomeAvani
1
SIGA a Biotech breakout last summer- then breakdown ? reversalAs shown on the daily chart dating back to last summer SIGA has been on a persistent decline since the cooling down from the parabolic breakout last summer. Is there a repeat in the picture? Fundamentally, earnings continue to be weak. much of the stock is held by insiders and the whole monkey pox thing is settled down although the main product may have use in malaria, leper's disease or whatever other orphan use it has indications by the FDA and its foreign counterparts. The technical picture is that it is sitting just above support shown by the Supply Demand Zone indicator of Luxalgo having double bottomed and now a bit above it. The volume indicator shows a mild increase in buying volume in the past couple of weeks. Price is more than one standard deviation below the long-term anchored VWAP in the undervalued over-sold zone. With a weak biotechnology company where insiders have a fair portion of the shares, manipulation can occur. Once a price rise issues short sellers will buy to cover, and retail traders will jump on board, insiders will "manufacture" a catalyst to prime the pump further. At some point, the run-up will stall, and the implode itself. I will get on the ride early, a biotechnology speculative trades are in my playbook. The stop loss here is below the demand zone while the target is the 50% retracement of the downtrend drawn onto the chart by the Fibonacci Retracement tool.
NASDAQ:SIGALong
by AwesomeAvani
EYPT EyePoint Pharmaceutics LONGEYPT is now on another breakout on the 2h chart similar to what occurred from mid-December to mid-January. On the indicators the MACD shows the K/D lines on a steep upward slope. For me, what set off my interest was a relative volume scan that produced this stock on the list. The relative volume this week and consequential accumulation triggered the breakout with those volume spikes Fundamentally, EYPT had a catalyst as it completed one phase of its FDA clinical trials for a treatment for macular degeneration, a debilitating eye disease of the elderly. The potential market is several multiples of the stock's current market cap. This company is a takeover candidate as it is young without a big pipeline but with upside potential. The relative volume of 4X to 8X is a sure sign that buying pressure will move the price. Price has crossed the SMA50 just as it did last winter. The price is up 40% or more this week. Could this be a pump and dump? Maybe. For sure it is a speculation play just like many NASDAQ penny biotech stocks For mem the price action of last winter with a 120% gain in one month is reassurance for this time around with some hopeium thrown into the mix with the technical analysis. I will buy a call option under the current price with the 4/21 expiration and leverage the speculation a bit. In the past day, this option rose 67% based on the price surge of the underlying stock.
NASDAQ:EYPTLong
by AwesomeAvani
3
Harvard Bioscience: Bouncing Higher From Multiple-Year SupportI zoomed all the way out to the monthly chart to show the long-term support levels. We can see that HBIO is bouncing higher from a multi-year support level in the $2 range. The MACD (middle of the chart) didn't confirm an upward trend yet. However, the MACD did confirm the upward trend on the weekly chart. It looks like the blue monthly MACD line is close to crossing above the red signal line. The purple RSI line on the bottom of the chart is pointing upward, which is bullish. This indicates that we could see a long-term continuation of the rally which began in December/January. Click on the link below for a detailed article. HBIO has a low valuation with strong expected EPS growth. This is likely to drive the stock higher IMO.
NASDAQ:HBIOLong
by Zman1175
$SAGE: strong base, upcoming catalysts$SAGE is an interesting stock here, has pending catalysts for mid 2023, which fit the expectations from the Time@Mode technical pattern at hand here. Consider the volatility of these biotech names when entering, stock could move huge after data comes out (up or down) but odds are good that it breaks to the upside given the technical pattern suggesting the smart money has been accumulating stock. Upcoming catalysts: SAGE-217 - (SHORELINE) Major Depressive Disorder (MDD) Phase 3 additional data due in mid-2023. Zuranolone (SAGE-217) Major depressive disorder (MDD) and Postpartum Depression PDUFA priority review date of August 5, 2023. Best of luck! Cheers, Ivan Labrie.
NASDAQ:SAGELong
by IvanLabrie
1
The Future of Crypto MarketCap: TA to Navigating the 2030 AgendaGreetings fellow traders and investors, The world events of the past year have had a profound impact on the global economy, and the crypto market has not been immune to these effects. As we move forward into the next period of capitalization, it is important to take a closer look at the current state of the crypto market and how it may be affected by the events unfolding around us. In this analysis, I will examine some of the key factors that are likely to shape the crypto market in the coming months, including the ongoing COVID-19 pandemic, geopolitical tensions, and the transition to a digital economy. I will also explore some of the potential opportunities and challenges that traders and investors may encounter in this dynamic and rapidly evolving landscape. Whether you are a seasoned trader or a newcomer to the crypto market, I believe that this analysis will provide you with valuable insights and actionable strategies for navigating the challenges and opportunities of the next capitalization period. So join me as we explore the future of the crypto market together, and let's uncover the hidden gems and potential profits that lie ahead. Thank you for your attention, and let's get started! We established great support at 750B, distribution was set, and we are now in an uptrend. This may be short lived after the events around us unfolding. The reactions of these events unfold slowly but will have a massive impact on the way we live. It's no secret that this is modern warfare. There is a lot of uncertainty with our global currency, the USD. From it not becoming the figure of value of the Saudi Oil Barrel to China leaping into taking the throne. It won't be long before news arouses over the "printing" of dollars from other countries such as Venezuela that they have officially figured out how to perfectly replicate it. This is pure speculation by the way. But it will play out. Banks will have "outages" which could last up to 3 days. Once that is survived, we may be presented with digitalizing the USD, and other world currencies. How will this play out? Well, I am not Cryptodamous. But I will pretend that I am. Uptrend: | Ends May 2023 | The speculation of uncertainty with the USD, people "Preparing" etc. will cause the market to go back to 1.5T, this will be short lived, and this is where the media will cover it, everyone will start to buy in again. This is your indicator to sell. Downtrend: | May 2023 - Nov. 2023 | Within 33 days, a new plannedemic will start to become mainstream. What is it, not sure... Could be Anthrax. If it's Anthrax, well it will start off with Animals being infected by polluted soil and water. What can cause this? Of course, not train derailments leaking into our soil and rivers that interconnect with all major water sources for our (US) farmland. But we will be blamed for our carbon footprint. The collateral damage will be a worldwide event. Food shortages, more control and possibly the first ever worldwide internet shortage. If what we are ingesting is infected, well then, we are also infected. All water above ground will be vulnerable. (Advice to buy land that you can tap a water well into) This will last for 6-8 months. This will correct the market into what everyone was expecting. $12k BTC. (The potential to Flash wick into $7k exists - this will only last 2 hours). Overall, this will place the total crypto market cap at $565B The new Bull Cycle: | Nov. 2023 - Dec. 2025 | The introduction to a new form of control. Digitalizing the US dollar. The people will catch up to this soon as they come to realization that you have 0 privacy. Your money expires. All your whereabouts will be monitored. But most importantly, taxing our carbon footprint. We are the first generation of humans to live life like this. This is new to everyone and although we can look at the past for the rise and fall of nations, we have the technology to break out of this system and treat Bitcoin as the true Digital "Gold." All the above is not trading advice. Use TA to accurately make your trading decisions. Freedom doesn't have a price. But if it did, it's not worth less than 10 Trillion :) and people will pay 100 Trillion :)
CRYPTOCAP:TOTAL
by jovani7919
MRNA | This is a BUY | BOUNCEModerna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
NASDAQ:MRNALong
by DivergenceSeeker
3
Young biotech leader $IMCR with good VCPImmunocore Holdings is a commercial-stage T cell receptor biotechnology company working to develop and commercialize transformative medicines for oncology, infectious diseases and autoimmune and inflammation diseases. In a confirmed uptrend, yesterday signaled a good pivot buy where I placed an initial position. I liked the volatility contraction pattern and the bullish divergence with the 10-day ROC prior to the breakout, and now I'll wait for the follow through action to add to the position. Lets wait and see.
NASDAQ:IMCRLong
by dpuleo19